Sartorius Stedim Biotech Maintains Growth Momentum in H1 2026

The supplier of technologies and consumables for the biopharmaceutical industry, Sartorius Stedim, recorded strong commercial momentum in the first half of 2026. Driven by sustained demand in its recurring activities and a recovery in equipment sales, the group continued to deliver profitable growth while navigating regulatory developments in the United States.

Solid Performance for Sartorius Stedim Despite External Headwinds

Sales of Sartorius Stedim reached €1.527 billion, representing an increase of 2.5% on a reported basis and 6.4% at constant exchange rates. Profitability also improved, with current EBITDA rising by 3.7% to €479 million. This translated into a current EBITDA margin of 31.4%, up 0.4 percentage points compared with the same period last year. Net income showed particularly strong growth, climbing 17.6% to €181 million.

These results reflect the group’s resilience and its ability to sustain performance acrosSartorius Stedim core activities, even in a complex regulatory environment.

Impact of U.S. Tariff Decision and Outlook Confirmed

The half-year performance was affected by a decision from the U.S. Supreme Court to invalidate certain tariffs. Following the ruling, Sartorius Stedim Biotech received a reimbursement and chose to pass this benefit on to its customers by refunding and compensating previously applied surcharges. These adjustments were recorded as reductions in both revenue and cost of sales.

As a result, reported revenue growth was temporarily impacted, particularly in the Americas region. Growth in this region stood at 0.8% at constant exchange rates but would have reached 5.4% excluding the compensation measures.

Despite these effects, the group has confirmed all its annual financial targets. Sartorius Stedim continues to expect revenue growth of between 6% and 10% at constant exchange rates. Taking into account the estimated impact of customer compensation—up to €35 million—growth is anticipated to fall within the lower half of this range. The EBITDA margin outlook remains unchanged, with expectations set slightly above 31%.

Overall, the company maintains a stable trajectory, balancing operational performance with customer-focused decisions.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Boursorama. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.